Novel Treatment Advances and Approaches
in Rheumatoid Arthritis: Personalizing Therapy
for Improved Clinical and Economic Outcomes
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session from the 2018 Spring Managed Care Forum. If you
participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from August 10, 2018 to August 10, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals
RA is a long-lasting autoimmune disorder that occurs when the immune
system mistakenly attacks the body's own tissues. It typically
results in warm, swollen, and painful joints, and pain and stiffness
often worsen following rest. According to the ACR, it is estimated
that over 1.3 million people suffer from RA in the United States.
Treatment regimens vary and carry important differences between
therapeutic options that are clinically relevant to healthcare
providers. Only about 1/3 of patients treated for RA ever achieve
clinical remission. The remaining patients can experience continuous
disease progression and disability. In addition, many patients will
have an inadequate response or can become intolerant to the widely
used anti-TNF therapies. Fortunately, new and emerging treatment
strategies may offer additional therapeutic options to address the
unmet needs of these patients. Clinicians have recently been
equipped with more treatment options, including IL-6 receptor
antagonists. These new options have shown improved efficacy and
safety in RA, and healthcare professionals must be educated on these
agents and the potential risks that come along with any treatment
option. This presentation on integrating emerging therapies into the
treatment paradigm will address this gap in knowledge by providing
attendees with updated treatment strategies, tools, guidelines, and
successful evidence-based treatment approaches from recent clinical
Upon completion of this
activity, participants will be able to:
Analyze the efficacy and safety data
of current and emerging biologic therapies, including IL-6
inhibitors, for the treatment of moderate-to-severe rheumatoid
arthritis (RA) for achieving individualized treatment goals
Examine the proinflammatory cellular
and cytokine networks underlying localized and systemic RA
Tailor treatment regimens for
moderate-to-severe RA based on ongoing monitoring of disease
activity, functional status, treatment response, and other
Interpret results of decision
support tools with health plan affiliated rheumatology
professionals to improve outcomes for patients with RA
Explore strategies to monitor and
manage adverse events associated with newer therapies in RA
management in order to improve patient adherence
||Jeffrey Curtis, MD, MS,
Marguerite Jones Harbert – Gene Ball Endowed Professor
UAB Division of Clinical Immunology & Rheumatology
has no relevant financial relationships to disclose. His
presentation has been peer reviewed for any bias.
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This presentation is supported by an
educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue